

ACUTE MYELOID LEUKEMIA

An Acute Illness Requires Rapid Results

ARUP Laboratories' Rapid Acute Myeloid Leukemia Targeted Therapy Mutation Panel offers a quick turnaround time, which is critical in the timely identification of prognostic markers and advantageous for immediate patient management. This panel should be ordered upon initial diagnosis or overt relapse of acute myeloid leukemia (AML) for immediate management guidance. This test is not intended for the detection of minimal residual disease.

3017050 | Rapid Acute Myeloid Leukemia Targeted Therapy Mutation Panel

Our rapid AML test assesses regions from nine genes with known clinical significance in hematologic malignancies and therefore aids in the diagnosis of AML subtypes.

Results are reported within 3 to 7 days.

ADDITIONAL TESTING

Order for subsequent or more comprehensive analysis.

3016621 | Myeloid Malignancies Mutation and Copy Number Variation Panel by Next Generation Sequencing

ARUP's Myeloid Malignancies Mutation and Copy Number Variation Panel by Next Generation Sequencing is designed to detect sequence variants, copy number alterations (gains or losses), and copy number-neutral loss of heterozygosity (CN-LOH). In addition to targeting specific genes, this assay detects and reports relevant copy number variants (CNVs) down to 5 Mb from across the genome. This test covers all of the latest variants relevant for diagnosis and classification, as well as emerging biomarkers that may inform clinical management.

RAPID
RESULTS LEAD
TO TIMELY
TREATMENT.
LEARN MORE:

